


# Challenges and Opportunities for Managing Hemophilia



Jointly sponsored/  
coprovided by



with the




Supported by an  
educational grant from  
Novo Nordisk, Inc.



Welcome to the continuing education activity entitled “Challenges and Opportunities for Managing Hemophilia”. We are pleased to provide you with what we hope will be an informative and meaningful program.

We would like to acknowledge that this activity is supported by an educational grant from Novo Nordisk and we would like to thank them for their support.

## Continuing Education Information



### **Physician Credit**

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Medical Education Resources (MER), Specialty Healthcare Benefits Council, and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.

### **Credit Designation**

Medical Education Resources designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Pharmacy Credit**

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 2.0 contact hours (0.20 CEUs) of the Accreditation Council for Pharmacy Education.  
(Universal Activity Number - 0816-9999-13-001-L01-P)

This activity is certified as Knowledge-based CPE.

### **Nursing Credit**

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This CE activity provides 2.0 contact hours of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 2.0 contact hours.


### **Case Manager Credit**

This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 2 CE contact hours.

Activity code: W0001222  
Approval Number: 20134115

Continuing education for this activity is provided by Medical Education Resources, or M-E-R; they have designated this activity for two credit hours for physicians, pharmacists, nurses, and case managers.


Financial Disclosures—The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this CME activity:



Name of Faculty	Reported Financial Relationship
Craig Kessler, MD	No financial relationships to disclose
Steven W. Pipe, MD	Grants/Research Support: Pfizer Inc. Consulting Fees: Pfizer Inc., Novo Nordisk, Baxter, Grifols, CSL Behring, Biogen Idec
Amy Shapiro, MD	Grants/Research Support: Adventrix, Bayer, Baxter, Biogen Idec, Bio Products Laboratory, CSL Behring, Inspiration, Kedrion Biopharma, Novartis, and Octopharma Consultant/Advisory Board: Baxter, Novo Nordisk, Bayer, Biogen Idec, Inspiration, LFB Biotechnologies
Regina Butler, RN	Consulting Fees: Biogen Idec
Sue Geraghty, RN, MBA	Consulting Fees: Novo Nordisk, Baxter BioScience, Pfizer; Speakers' Bureau: Novo Nordisk
Karen Wulff, RN	Consulting Fees: Baxter BioScience, CLS Behring, Octapharma, Bayer Speakers' Bureau: Novo Nordisk, Bayer
Bill Ax	No financial relationships to disclose
Joan Couden, BSN, RN	Speakers' Bureau/Salary: Walgreens Infusion Services
Terry Whiteside, RPh	No financial relationships to disclose
James A. Jorgenson, RPh, MS, FASHP	No financial relationships to disclose
Edmund Pezalla, MD, MPH	Salary: Aetna
Celynda Tadlock, PharmD MBA	No financial relationships to disclose

Program faculty reported financial relationships with commercial interests whose products or services may be mentioned in this continuing education activity.

Financial Disclosures—The planners reported the following financial relationships with commercial interests whose products or services may be mentioned in this CME activity:




*The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this CME activity:*

Name of Content Manager	Reported Financial Relationship
Joe Eichenholz (Specialty Healthcare Benefits Council)	No financial relationships to disclose
Nathan Scott (Medical Education Resources)	No financial relationships to disclose
Michelle Rice (National Hemophilia Foundation)	No financial relationships to disclose
Steven Casebeer (Impact Education, LLC)	No financial relationships to disclose
Keith Engelke (Impact Education, LLC)	No financial relationships to disclose

Likewise, program planners reported financial relationships with commercial interests whose products or services may be mentioned.


## Agenda



<b>Presentation Title</b>	<b>Perspective</b>
<i>Current Practices and Treatment Recommendations for the Management of Hemophilia</i>	<i>Hematologist</i>
<i>Collaborating to Improve Patient Management</i>	<i>HTC Nurse Coordinator</i>
<i>Opportunities with Specialty Pharmacy/Home Infusion Services</i>	<i>Specialty Pharmacy/Home Infusion Provider</i>
<i>Strategies for Managed Care and Other Payers to Improve Hemophilia Patient Outcomes</i>	<i>Managed Care Provider</i>
<i>Case Study Challenges and Opportunities</i>	<i>All Faculty</i>

This program, “Challenges and Opportunities for Managing Hemophilia,” includes a number of presentations. First, we will get a hematologist’s perspective on “Current Practices and Treatment Recommendations for the Management of Hemophilia”. Then a Hemophilia Treatment Center, or H-T-C, nurse coordinator will provide a perspective on “Collaborating to Improve Patient Management”. A representative from the specialty pharmacy and home infusion field will provide information on “Opportunities with Specialty Pharmacy/Home Infusion Services”. Next, we will provide a managed care perspective about “Strategies for Managed Care and Other Payers to Improve Hemophilia Patient Outcomes”. Finally, the faculty will present and comment on “Case Study Challenges and Opportunities.”

# Presenters



**Joe Eichenholz**  
*Specialty Healthcare Benefits Council*

**Steven W. Pipe, MD**  
*University of Michigan Hemophilia & Coagulation Disorders Program*

**Amy D. Shapiro, MD**  
*Indiana Hemophilia & Thrombosis Center*

**Regina Butler, RN**  
*Hemostasis & Thrombosis Center at the Children's Hospital of Philadelphia*


**Sue Geraghty, RN**  
*Mountain States Regional Hemophilia & Thrombosis Center*

**Bill Ax**  
*Accredo Hemophilia Health Services*

**Joan Couden, BSN, RN**  
*Bleeding Disorder Program for Walgreens Infusion Services in Hemophilia*

The presenters for this continuing education activity include a nationally representative sample of professionals in the medical, pharmaceutical, and healthcare payer fields.

# Presenters



**Terry Whiteside, RPh**  
*CVS Caremark*

**James Jorgenson, RPh, MS, FASHP**  
*Visante, Inc.*

**Edmund Pezalla, MD, MPH**  
*Aetna, Inc.*

**Celynda G. Tadlock, PharmD, MBA**  
*Coventry Health Care*

***Additional faculty who contributed to the entirety of the program but, for personal reasons, were unable to present at webcasts:***


**Craig Kessler, MD**  
*Comprehensive Hemophilia and Thrombophilia Treatment Center, Georgetown University*

**Karen Wulff, RN**  
*Louisiana Comprehensive Hemophilia Care Center*

*No text.*



## Educational Objectives




- Differentiate general hemophilia from hemophilia with inhibitors, and identify the unique challenges associated with inhibitors.
- Evaluate the impact of changes in the treatment of pediatric and adult hemophilia on your own organization.
- Identify opportunities to engage additional clinical and financial stakeholders in the medical care and management of pediatric and adult hemophilia patients, thereby increasing the effectiveness of all participants in the care process.
- Evaluate current formulary development and management techniques and specialty pharmacy arrangements and incorporate new concepts to improve the quality and cost effectiveness of care for both pediatric and adult hemophilia patients.
- Improve integration of available resources, such as HTC's, in clinical treatment and overall patient management.

Upon completion of the entire 2013 continuing education activity, Sections 1 through 6, participants will be able to:

1. Differentiate general hemophilia from hemophilia with inhibitors, and identify the unique challenges associated with inhibitors;
2. Evaluate the impact of changes in the treatment of pediatric and adult hemophilia on your own organization;
3. Identify opportunities to engage additional clinical and financial stakeholders in the medical care and management of pediatric and adult hemophilia patients, thereby increasing the effectiveness of all participants in the care process;
4. Evaluate current formulary development and management techniques and specialty pharmacy arrangements and incorporate new concepts to improve the quality and cost effectiveness of care for both pediatric and adult hemophilia patients; and
5. Improve integration of available resources, such as HTC's, in clinical treatment and overall patient management.





## **Post-Test and CE Credit**

**Upon completion of all 6 learning activities, please visit**  
**[www.shbc.us](http://www.shbc.us)**  
**to complete a post-test and evaluation**  
**and receive two CE credit hours**

To earn continuing educational units for this activity, upon completion of Sections 1 through 6, please visit The Specialty Healthcare Benefits Council website at [www.shbc.us](http://www.shbc.us). There you will be able to review a peer-reviewed article from The American Journal of Pharmacy Benefits which is also part of this enduring CE program. You can then complete a post-test and evaluation and receive two continuing education credit hours.